特立帕肽在药物相关性颌骨坏死（MRONJ）中的作用。
Role of Teriparatide in Medication-Related Osteonecrosis of the Jaws (MRONJ).
作者信息
Kwon Yong-Dae, Kim Deog-Yoon
机构信息
Center for Refractory Jawbone Diseases, Department of Oral & Maxillofacial Surgery, Kyung Hee University Dental Hospital, Seoul 02447, Korea.
Department of Nuclear Medicine, Kyung Hee University Hospital, Seoul 02447, Korea.
出版信息
Dent J (Basel). 2016 Nov 9;4(4):41. doi: 10.3390/dj4040041.
Abstract
While the optimal treatment concept of medication-related osteonecrosis of the jaws (MRONJ) is still in debate, several adjunct therapies have been introduced. Among these adjunctive measures, recombinant human parathyroid hormone (rhPTH, teriparatide) seems to be the most promising treatment modality. Several studies have presented the beneficial effect of short-term teriparatide; they have shown an improved level of bone markers and radiographic evidence of bone healing. Although clinical validation by a controlled trial with prospective design would be essential, short-term teripratide therapy would be a good treatment option for MRONJ patients with impaired bone remodeling.
摘要
虽然颌骨药物相关性骨坏死（MRONJ）的最佳治疗理念仍存在争议，但已引入了几种辅助治疗方法。在这些辅助措施中，重组人甲状旁腺激素（rhPTH，特立帕肽）似乎是最有前景的治疗方式。多项研究表明了短期使用特立帕肽的有益效果；这些研究显示骨标志物水平有所改善，并有骨愈合的影像学证据。尽管前瞻性设计的对照试验进行临床验证至关重要，但短期特立帕肽治疗对于骨重塑受损的MRONJ患者将是一个不错的治疗选择。
相似文献
1
Role of Teriparatide in Medication-Related Osteonecrosis of the Jaws (MRONJ).特立帕肽在药物相关性颌骨坏死（MRONJ）中的作用。
Dent J (Basel). 2016 Nov 9;4(4):41. doi: 10.3390/dj4040041.
2
[The recombinant human parathyroid hormone, teriparatide as an alternative remedy for the medication-related osteonecrosis of the jaw].[重组人甲状旁腺激素特立帕肽作为颌骨药物性骨坏死的替代治疗方法]
Orv Hetil. 2023 Sep 10;164(36):1406-1415. doi: 10.1556/650.2023.32861.
3
Adjunctive recombinant human parathyroid hormone agents for the treatment of medication-related osteonecrosis of the jaw: a report of three cases.辅助性重组人甲状旁腺激素制剂治疗药物相关性颌骨坏死：3例报告
J Korean Assoc Oral Maxillofac Surg. 2024 Apr 30;50(2):103-109. doi: 10.5125/jkaoms.2024.50.2.103.
4
Short-Term Teriparatide and Recombinant Human Bone Morphogenetic Protein-2 for Regenerative Approach to Medication-Related Osteonecrosis of the Jaw: A Preliminary Study.短期特立帕肽和重组人骨形态发生蛋白-2 用于药物相关性颌骨坏死的再生治疗：一项初步研究。
J Bone Miner Res. 2017 Dec;32(12):2445-2452. doi: 10.1002/jbmr.3237. Epub 2017 Sep 18.
5
Treatment of Medication-Related Osteonecrosis of the Jaw Around the Dental Implant With a Once-Weekly Teriparatide: A Case Report and Literature Review.每周一次使用特立帕肽治疗牙种植体周围药物相关性颌骨坏死：一例报告及文献综述
J Oral Implantol. 2019 Oct;45(5):403-407. doi: 10.1563/aaid-joi-D-19-00040. Epub 2019 Aug 20.
6
The role, efficacy and outcome measures for teriparatide use in the management of medication-related osteonecrosis of the jaw.特立帕肽在药物相关性颌骨坏死管理中的作用、疗效和结局评估。
Int J Oral Maxillofac Surg. 2021 Apr;50(4):501-510. doi: 10.1016/j.ijom.2020.07.021. Epub 2020 Aug 14.
7
Evaluation of the effect of teriparatide therapy on mandibular fracture healing in rats with medication-related osteonecrosis of the jaw.评价特立帕肽治疗药物相关性颌骨骨坏死大鼠下颌骨骨折愈合的效果。
Clin Oral Investig. 2019 Nov;23(11):3987-3993. doi: 10.1007/s00784-019-02830-2. Epub 2019 Feb 4.
8
Medication-related osteonecrosis of the jaw: evolving research for multimodality medical management.药物相关性颌骨坏死：多模态医学管理的研究进展。
Support Care Cancer. 2024 Mar 5;32(4):212. doi: 10.1007/s00520-024-08388-4.
9
Radiographic bone loss and the risk of medication-related osteonecrosis of the jaw (MRONJ) in multiple myeloma patients-A retrospective case control study.多发性骨髓瘤患者的影像学骨丢失与颌骨药物相关性骨坏死（MRONJ）风险——一项回顾性病例对照研究
Spec Care Dentist. 2018 Nov;38(6):356-361. doi: 10.1111/scd.12318. Epub 2018 Sep 8.
10
Treatment of Osteonecrosis of the Jaw.颌骨骨坏死的治疗
J Craniofac Surg. 2015 Oct;26(7):e575-7. doi: 10.1097/SCS.0000000000002127.
引用本文的文献
1
Supra-Physiological Levels of Magnesium Counteract the Inhibitory Effect of Zoledronate on RANKL-Dependent Osteoclastogenesis.超生理水平的镁可抵消唑来膦酸对RANKL依赖性破骨细胞生成的抑制作用。
Biology (Basel). 2025 May 11;14(5):533. doi: 10.3390/biology14050533.
2
Treatment of Medication-Related Osteonecrosis of the Jaw Without and With the Use of Advanced Platelet-Rich Fibrin: A Retrospective Clinical Study.不使用和使用高级富血小板纤维蛋白治疗药物相关性颌骨坏死：一项回顾性临床研究
J Funct Biomater. 2025 May 14;16(5):180. doi: 10.3390/jfb16050180.
3
Treatment period and changes in bone markers according to the application of teriparatide in treating medication-related osteonecrosis of the jaw.根据特立帕肽在治疗药物相关性颌骨坏死中的应用情况，观察治疗周期及骨标志物的变化。
BMC Oral Health. 2025 Apr 11;25(1):528. doi: 10.1186/s12903-025-05867-w.
4
[Osteoporosis-Definition, risk assessment, diagnosis, prevention and treatment (update 2024) : Guidelines of the Austrian Society for Bone and Mineral Research].[骨质疏松症——定义、风险评估、诊断、预防与治疗（2024年更新版）：奥地利骨与矿物质研究学会指南]
Wien Klin Wochenschr. 2024 Oct;136(Suppl 16):599-668. doi: 10.1007/s00508-024-02441-2. Epub 2024 Oct 2.
5
Local re-activation of osteoclast differentiation as a novel therapeutic strategy for osteonecrosis of the jaw.局部重新激活破骨细胞分化作为颌骨坏死的一种新型治疗策略。
Front Endocrinol (Lausanne). 2024 Jul 19;15:1447314. doi: 10.3389/fendo.2024.1447314. eCollection 2024.
6
Reduction of MRONJ risk after exodontia by virtue of ozone infiltration: A randomized clinical trial.通过臭氧浸润降低拔牙后 MRONJ 的风险：一项随机临床试验。
Oral Dis. 2024 Nov;30(8):5183-5194. doi: 10.1111/odi.15006. Epub 2024 May 29.
7
Mechanisms and Treatment Options for Hyperthyroid-Induced Osteoporosis: A Narrative Review.甲状腺功能亢进症所致骨质疏松症的发病机制与治疗选择：一篇叙述性综述
Cureus. 2023 Nov 14;15(11):e48798. doi: 10.7759/cureus.48798. eCollection 2023 Nov.
8
Anti-resorptive therapy in the osteometabolic patient affected by periodontitis. A joint position paper of the Italian Society of Orthopaedics and Traumatology (SIOT) and the Italian Society of Periodontology and Implantology (SIdP).抗吸收治疗在患有牙周炎的骨代谢患者中的应用。意大利矫形外科和创伤学会（SIOT）与意大利牙周病学和种植学会（SIdP）的联合立场文件。
J Orthop Traumatol. 2023 Jul 15;24(1):36. doi: 10.1186/s10195-023-00713-7.
9
Medication-induced osteonecrosis of the jaw: a review of cases from the Food and Drug Administration Adverse Event Reporting System (FAERS).药物性颌骨坏死：来自食品和药物管理局不良事件报告系统（FAERS）的病例回顾。
BMC Pharmacol Toxicol. 2023 Mar 6;24(1):15. doi: 10.1186/s40360-023-00657-y.
10
Pharmacological intervention of the FGF-PTH axis as a potential therapeutic for craniofacial ciliopathies.成纤维细胞生长因子-甲状旁腺激素轴的药理学干预作为一种治疗颅面纤毛病的潜在疗法。
Dis Model Mech. 2022 Aug 1;15(8). doi: 10.1242/dmm.049611. Epub 2022 Aug 16.
本文引用的文献
1
Position Statement: Drug Holiday in Osteoporosis Treatment with Bisphosphonates in South Korea.立场声明：韩国双膦酸盐治疗骨质疏松症中的药物假期
J Bone Metab. 2015 Nov;22(4):167-74. doi: 10.11005/jbm.2015.22.4.167. Epub 2015 Nov 30.
2
Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw: preliminary findings.特立帕肽治疗可改善晚期双膦酸盐相关颌骨坏死的症状：初步研究结果。
Int J Oral Maxillofac Surg. 2015 Dec;44(12):1558-64. doi: 10.1016/j.ijom.2015.07.018. Epub 2015 Aug 21.
3
Anabolic effects of PTH and the 'anabolic window'.甲状旁腺激素的合成代谢作用和“合成代谢窗口期”。
Trends Endocrinol Metab. 2015 Mar;26(3):111-3. doi: 10.1016/j.tem.2015.01.004. Epub 2015 Feb 5.
4
Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw.6个月特立帕肽治疗对顽固性双膦酸盐相关颌骨坏死的独特作用。
Osteoporos Int. 2014 May;25(5):1625-32. doi: 10.1007/s00198-014-2622-8. Epub 2014 Feb 20.
5
Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.绝经后骨质疏松症妇女使用地舒单抗和特立帕肽治疗 2 年（DATA 扩展研究）：一项随机对照试验。
J Clin Endocrinol Metab. 2014 May;99(5):1694-700. doi: 10.1210/jc.2013-4440. Epub 2014 Feb 11.
6
The effect of bisphosphonate therapy on neutrophil function: a potential biomarker.双膦酸盐治疗对中性粒细胞功能的影响：一种潜在的生物标志物。
Int J Oral Maxillofac Surg. 2013 May;42(5):619-26. doi: 10.1016/j.ijom.2012.12.011. Epub 2013 Feb 8.
7
Osteonecrosis of the mandible associated with bevacizumab therapy.与贝伐珠单抗治疗相关的下颌骨骨坏死。
Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Jun;115(6):e32-6. doi: 10.1016/j.oooo.2013.02.001. Epub 2013 Apr 6.
8
Factors predicting the prognosis of oral alendronate-related osteonecrosis of the jaws: a 4-year cohort study.预测口腔阿仑膦酸钠相关性颌骨骨坏死预后的因素：一项 4 年队列研究。
Head Neck. 2013 Dec;35(12):1787-95. doi: 10.1002/hed.23235. Epub 2013 Mar 18.
9
Teriparatide therapy for bisphosphonate-associated osteonecrosis of the jaw in an elderly Japanese woman with severe osteoporosis.特立帕肽治疗老年日本严重骨质疏松症伴双膦酸盐相关性颌骨骨坏死 1 例
Clin Drug Investig. 2012 Aug 1;32(8):547-53. doi: 10.1007/BF03261908.
10
Lack of response to teriparatide therapy for bisphosphonate-associated osteonecrosis of the jaw.对特立帕肽治疗双膦酸盐相关颌骨坏死无反应。
Osteoporos Int. 2013 Feb;24(2):731-3. doi: 10.1007/s00198-012-1918-9. Epub 2012 Mar 8.
Zotero 插件